Lincoff, A.M.

patient infarction trial death intervention treatment study event eptifibatide percutaneou stroke outcome elevation group pursuit 30 days placebo angina syndrome heparin ck-mb heart table /iiia therapy creatine platelet baseline investigator thrombocytopenia analysis ratio mortality model glycoprotein circulation result epti fibatide characteristic revascularization end point fibatide procedure population month point kinase difference treatment e ffect creatine kinase-mb level reduction eur heart j randomized infusion st-segment elevation baseline characteristics abciximab incidence signi kinase-mb nonhemorrhagic stroke disease st-segment 6- month mortality tranilast 30- europe region america nonhemorrhagic strategy effect angioplasty follow-up receptor predictor factor pursuit trial di fferences